[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1993

Neuropharmacologic Basis for Clozapine's Unique Profile

Author Affiliations

University of Michigan Hospitals Ann Arbor, MI 48109-0120
Glen Oaks, NY

Arch Gen Psychiatry. 1993;50(2):158-159. doi:10.1001/archpsyc.1993.01820140084012
Abstract

To the Editor.—  In comparison with standard neuroleptics, clozapine is more effective in decreasing positive and negative symptoms in treatmentrefractory schizophrenic patients, and causes significantly fewer parkinsonian side effects and less tardive dyskinesia.1 In recent months, three distinct neurochemical hypotheses to explain clozapine's unique profile have been discussed in the Archives.2-4 Farde et al2 propose that clozapine's lower D2 dopamine receptor binding may explain the infrequent extrapyramidal syndromes (EPSs), and its higher D1 dopamine receptor binding may explain its superior efficacy. Meltzer and Stockmeier3 suggest that clozapine's significant serotonin (5-HT2) antagonist activity may explain both its unique properties. Pickar et al4 propose that clozapine's potent α2-noradrenergic antagonist activity (in addition to its anti-5-HT2 activity) may be relevant to its unique profile. Clozapine's greater affinity for the D4 dopamine receptor site5 has been implicated as well. Recent data

First Page Preview View Large
First page PDF preview
First page PDF preview
×